ArticleEuropean urology open science2025

Real-life Use of Cabozantinib in Front-line therapy for Metastatic Renal Cell Carcinoma: The CabFRONT Study (Meet-URO 24).

Marco Stellato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.